SYNLAB AG |
Market Closed -
Other stock markets
|
After market 12:14:13 pm | |||
| 11.12 EUR | -0.54% |
|
11.16 | +0.36% |
| Jun. 04 | Hackers attack laboratory chain Synlab again: 'repercussions' for patients | DP |
| Jun. 04 | Hackers attack laboratory chain Synlab again - 'consequences' for patients | DP |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.22 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.63% | 2.67B | - | ||
| -22.94% | 7.77B | B+ | ||
| +76.99% | 4.51B | C+ | ||
| +6.87% | 2.76B | B- | ||
| -49.74% | 2.09B | B- | ||
| -18.15% | 1.72B | C- | ||
| -19.35% | 1.49B | A- | ||
| +18.29% | 1.22B | B+ | ||
| -44.77% | 1.12B | C+ | ||
| +20.68% | 1.05B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SYAB Stock
- Ratings SYNLAB AG
